AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28117141 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse CAP
Number of subjects: 50
Study 28117141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine CAP
Number of subjects: 50
Study 28117141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafine CAP
Number of subjects: 50
Study 28117141 — intervention group
Group type: COMPARATOR
Intervention: Filtered medical air
Number of subjects: 50
Study 25967848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54
Study 25967848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24314422 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (ACP) and medical treatment (group 1)
Number of subjects: 54
Study 24314422 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone (group 2)
Number of subjects: 54
Study 20304541 — intervention group
Group type: EXPERIMENTAL
Intervention: Alar base cinch suture
Number of subjects: 28
Study 20304541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cinch suture)
Number of subjects: 28
Study 20304541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 19370729 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program based on treadmill training associated with auditory and visual cues
Number of subjects: 40
Study 19370729 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation protocol using cues not associated with treadmill
Number of subjects: 40
Study 16838377 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 12
Study 16838377 — intervention group
Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 12
Study 15589640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous cryoablation
Number of subjects: 200
Study 15589640 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 200
Study 11247890 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Crohn's disease
Number of subjects: 32
Study 9236054 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant with subunit influenza vaccine
Number of subjects: 1807
Study 9236054 — intervention group
Group type: COMPARATOR
Intervention: Subunit influenza vaccine without MF59
Number of subjects: 1807
Study 8314169 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release bezafibrate 400 mg (n = 21)
Number of subjects: 40
Study 8314169 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 19)
Number of subjects: 40
Study 3518423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled subcutaneous catheters
Number of subjects: 88
Study 3518423 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters inserted over a guidewire
Number of subjects: 88
Study 3518423 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall catheter colonization
Number of subjects: 88
Study 3518423 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-associated bacteremia
Number of subjects: 88
Study 3518423 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters removed from febrile patients
Number of subjects: 88
Study 30252723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat + antioxidant
Number of subjects: 0
Study 30252723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat + placebo
Number of subjects: 0
Study 30252723 — intervention group
Group type: COMPARATOR
Intervention: No heat
Number of subjects: 0
Study 27322154 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective messaging intervention ('Pregnant Pause' video)
Number of subjects: 106
Study 27322154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive messaging intervention ('Vaccines for a Healthy Pregnancy' video)
Number of subjects: 106
Study 27322154 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (receipt of the Influenza Vaccine Information Statement)
Number of subjects: 106
Study 24802090 — intervention group
Group type: EXPERIMENTAL
Intervention: Five 1‐hr milieu communication teaching (MCT) sessions per week (daily treatment)
Number of subjects: 63
Study 24802090 — intervention group
Group type: COMPARATOR
Intervention: One 1‐hr milieu communication teaching (MCT) session per week (weekly treatment)
Number of subjects: 63
Study 24802090 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental linguistic mapping measured after 6 months of treatment
Number of subjects: 63
Study 22232129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer-Lignocaine
Number of subjects: 42
Study 22232129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20507378 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD+AB (enamel matrix derivative combined with autogenous bone)
Number of subjects: 40
Study 20507378 — intervention group
Group type: COMPARATOR
Intervention: EMD (control)
Number of subjects: 40
Study 17649651 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion model intervention activities
Number of subjects: 2343
Study 15982128 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional scenes presented parafoveally for 150-3000 ms
Number of subjects: 0
Study 15982128 — intervention group
Group type: COMPARATOR
Intervention: Neutral scenes presented parafoveally for 150-3000 ms
Number of subjects: 0
Study 12356338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 11
Study 12356338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11095258 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 122
Study 11095258 — intervention group
Group type: COMPARATOR
Intervention: Endometrial surveillance alone
Number of subjects: 122
Study 9456632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with trigger points technique
Number of subjects: 243
Study 9456632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 243
Study 1559737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine lotion
Number of subjects: 26
Study 1559737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream
Number of subjects: 26
Study 1559737 — intervention group
Group type: COMPARATOR
Intervention: Vehicle for ciclopirox olamine lotion
Number of subjects: 26
Study 1559737 — intervention group
Group type: COMPARATOR
Intervention: Vehicle for ciclopirox olamine cream
Number of subjects: 26
Study 4014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine (group 1, n = 8)
Number of subjects: 16
Study 4014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine sodium citrate (group 2, n = 8)
Number of subjects: 16
Study 31056705 — intervention group
Group type: EXPERIMENTAL
Intervention: URC102 (1-30 mg single dose for Koreans, 1-10 mg single dose for Caucasians)
Number of subjects: 54
Study 31056705 — intervention group
Group type: EXPERIMENTAL
Intervention: URC102 (1-20 mg once-daily for 7 days for 44 Koreans)
Number of subjects: 54
Study 29914413 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D 10 scale
Number of subjects: 2098
Study 26456955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LOR)
Number of subjects: 196
Study 26456955 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 196
Study 26456955 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 196
Study 26456955 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 196
Study 26456955 — intervention group
Group type: COMPARATOR
Intervention: Group I (VPA vs PHT)
Number of subjects: 196
Study 26456955 — intervention group
Group type: COMPARATOR
Intervention: Group II (LOR vs LEV)
Number of subjects: 196
Study 26456955 — intervention group
Group type: EXPERIMENTAL
Intervention: LOR and LEV combination
Number of subjects: 196
Study 23944602 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS) program: three bouts of 2‐min SS of the plantar flexors, 6 days a week for 5 weeks.
Number of subjects: 19
Study 23944602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 19
Study 22342538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 25 μg once daily
Number of subjects: 598
Study 22342538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 50 μg once daily
Number of subjects: 598
Study 22342538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg once daily
Number of subjects: 598
Study 22342538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg once daily
Number of subjects: 598
Study 22342538 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 μg twice daily
Number of subjects: 598
Study 22342538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 598
Study 20347836 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 113
Study 20347836 — intervention group
Group type: COMPARATOR
Intervention: Control (quiet relaxation time)
Number of subjects: 113
Study 18343264 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg
Number of subjects: 52
Study 18343264 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 5000 mg
Number of subjects: 52
Study 18343264 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 52
Study 18343264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16166187 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% CO2 inhalation
Number of subjects: 30
Study 16166187 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (control)
Number of subjects: 30
Study 12562571 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25-600 mg/day)
Number of subjects: 61
Study 12562571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 50 mg twice/day
Number of subjects: 1004
Study 10555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice/day
Number of subjects: 1004
Study 10555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice/day
Number of subjects: 1004
Study 10555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice/day
Number of subjects: 1004
Study 10555933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study 8916480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 1750
Study 8916480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1750
Study 31917607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant (up to 20 mg/d over 12 weeks)
Number of subjects: 268
Study 31917607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 268
Study 31917607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 31249709 — intervention group
Group type: EXPERIMENTAL
Intervention: Test adhesive (carbomer-based)
Number of subjects: 44
Study 31249709 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference adhesive (PVM/MA-based)
Number of subjects: 44
Study 31249709 — intervention group
Group type: COMPARATOR
Intervention: No adhesive
Number of subjects: 44
Study 28708074 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild nature video presentation
Number of subjects: 220
Study 28708074 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban nature video presentation
Number of subjects: 220
Study 28708074 — intervention group
Group type: COMPARATOR
Intervention: Non-nature control video
Number of subjects: 220
Study 26963851 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.1 mg) injected into the intermetatarsal space
Number of subjects: 58
Study 26963851 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected into the intermetatarsal space
Number of subjects: 58
Study 26963851 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.1 mg)
Number of subjects: 58
Study 24396284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 147
Study 24396284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer stocking system
Number of subjects: 147
Study 24396284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi layer short stretch bandage
Number of subjects: 147
Study 24396284 — intervention group
Group type: COMPARATOR
Intervention: Two layer short stretch bandages
Number of subjects: 147
Study 24396284 — intervention group
Group type: COMPARATOR
Intervention: Unna boots
Number of subjects: 147
Study 22141423 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 213
Study 22141423 — intervention group
Group type: COMPARATOR
Intervention: Community Control
Number of subjects: 213
Study 19011440 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 15
Study 19011440 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated patients (control)
Number of subjects: 15
Study 15990749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 481
Study 15990749 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 481
Study 12843167 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20 mg/d)
Number of subjects: 44
Study 12843167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900-1200 mg/d)
Number of subjects: 44
Study 12843167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (10 mg atorvastatin and 900 mg gemfibrozil)
Number of subjects: 44
Study 11013186 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK for secondary hyperopia
Number of subjects: 30
Study 8635380 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Morphine plus 25 mg Promethazine (M-P)
Number of subjects: 7
Study 8635380 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Morphine (M)
Number of subjects: 7
Study 8635380 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Morphine plus 10 mg Prochlorperazine (M-PC)
Number of subjects: 7
Study 8635380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study 1461870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (high doses)
Number of subjects: 0
Study 1461870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (high doses)
Number of subjects: 0
Study 1461870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (low doses)
Number of subjects: 0
Study 1461870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (low doses)
Number of subjects: 0
Study 3867301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation (24Gy) plus i.t. MTX, 6 doses (Modality A)
Number of subjects: 76
Study 3867301 — intervention group
Group type: EXPERIMENTAL
Intervention: i.t. MTX and ARA-C, 10 doses (6 weekly and 4 monthly) (Modality B)
Number of subjects: 76
Study 3867301 — intervention group
Group type: COMPARATOR
Intervention: Standard-risk (SR) therapy with PRED, VCR, ASPAR for remission induction and MP and MTX for maintenance
Number of subjects: 76
Study 3867301 — intervention group
Group type: COMPARATOR
Intervention: High-risk (HR) therapy with 4 drugs including DAUNO, PRED, VCR, and DAUNO for reinductions every 3 months
Number of subjects: 76
Study 3867301 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of cotrimoxazole
Number of subjects: 76
Study 29305245 — intervention group
Group type: EXPERIMENTAL
Intervention: supplemental home parenteral nutrition (sHPN)
Number of subjects: 47
Study 29305245 — intervention group
Group type: COMPARATOR
Intervention: best practice nutritional care and dietetic counselling (non-sHPN)
Number of subjects: 47
Study 29043918 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 58
Study 29043918 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 58
Study 26325232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 40
Study 26325232 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ICS
Number of subjects: 40
Study 25419743 — intervention group
Group type: EXPERIMENTAL
Intervention: Livestock/animal asset value
Number of subjects: 0
Study 25419743 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict-related traumatic events
Number of subjects: 0
Study 22859563 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost (CCB) with a median dose of 66 Gy and median overall treatment time (OTT) of 40 days
Number of subjects: 16
Study 22859563 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) with a median dose of 60 Gy and median OTT of 47 days
Number of subjects: 16
Study 22859563 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment time (OTT) ≤42 days
Number of subjects: 16
Study 22859563 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment time (OTT) ≥43 days
Number of subjects: 16
Study 19841476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelotanserin (up to 40 mg)
Number of subjects: 0
Study 17914653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.54 percent continuous wound infusion
Number of subjects: 310
Study 17914653 — intervention group
Group type: COMPARATOR
Intervention: Normal saline continuous wound infusion
Number of subjects: 310
Study 15983144 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT/MCT propofol
Number of subjects: 200
Study 15983144 — intervention group
Group type: COMPARATOR
Intervention: LCT propofol
Number of subjects: 200
Study 12850358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc PS vaccine (N=106)
Number of subjects: 160
Study 12850358 — intervention group
Group type: COMPARATOR
Intervention: Control group (TT only, N=54)
Number of subjects: 160
Study 10097952 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 million IU IFN alpha subcutaneously 5 times weekly and 6 million IU IL-2 subcutaneously twice weekly
Number of subjects: 0
Study 10097952 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 10097952 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 million IU IFN alpha and 6 million IU IL-2
Number of subjects: 0
Study 8904969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication in women (both normally cycling and those taking oral contraceptives)
Number of subjects: 2
Study 8904969 — intervention group
Group type: EXPERIMENTAL
Intervention: High estrogen phases in women
Number of subjects: 2
Study 8904969 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 2
Study 1651210 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 223
Study 1651210 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 223
Study 7093092 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 100 mg orally twice daily
Number of subjects: 19
Study 7093092 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 0.6 mg/kg intravenous dose
Number of subjects: 19
Study 30205445 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Nordic Walking (HI-NW) with Vitamin D supplementation (4000 IU/day or 800 IU/day)
Number of subjects: 42
Study 30205445 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Nordic Walking (MI-NW) with High Dose Vitamin D supplementation (4000 IU/day)
Number of subjects: 42
Study 30205445 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Nordic Walking (MI-NW) with Low Dose Vitamin D supplementation (800 IU/day)
Number of subjects: 42
Study 26507685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alitretinoin 30 mg once daily for up to 24 weeks
Number of subjects: 10
Study 25527262 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching Routine (SR)
Number of subjects: 18
Study 25527262 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up Routine (WR)
Number of subjects: 18
Study 25527262 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 18
Study 23377516 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray (CPS)
Number of subjects: 0
Study 19997953 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure hemorrhoidectomy (LH)
Number of subjects: 84
Study 19997953 — intervention group
Group type: COMPARATOR
Intervention: Conventional open hemorrhoidectomy (OH)
Number of subjects: 84
Study 18677673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification and pharmacological treatment
Number of subjects: 1510
Study 18677673 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1510
Study 15960709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral penicillin - 800,000 U penicillin G potassium twice daily for 12 days, repeated every 3 months for 1 year
Number of subjects: 100
Study 15960709 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine - 6 mg/kg bodyweight for 12 days, repeated every 3 months for 1 year
Number of subjects: 100
Study 15960709 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiseptic (betadine ointment)
Number of subjects: 100
Study 12505919 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV weight‐adjusted infusion of remifentanil (RIVA)
Number of subjects: 46
Study 12505919 — intervention group
Group type: COMPARATOR
Intervention: Target-controlled infusion for remifentanil (TCIR)
Number of subjects: 46
Study 11049237 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 123
Study 11049237 — intervention group
Group type: COMPARATOR
Intervention: Control (pethidine-inhalational entonox)
Number of subjects: 123
Study 9172806 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant (PBSCT)
Number of subjects: 76
Study 9172806 — intervention group
Group type: COMPARATOR
Intervention: Autologous Bone Marrow Transplant (ABMT)
Number of subjects: 76
Study 1825332 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-01 applied (T)
Number of subjects: 27
Study 1825332 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied (P)
Number of subjects: 27
Study 1825332 — intervention group
Group type: COMPARATOR
Intervention: Control sites (C)
Number of subjects: 27